Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Inclusion Criteria:

- Subject (man or woman) is ≥ 18 and ≤ 80 years old.

- Subject is diagnosed with RA as determined by meeting the the 2010 American College of
Rheumatology (ACR)/European League Against Rheumatism classification criteria for RA.

- Subject has RA duration of at least 3 months.

- Subject has active RA defined as ≥ 6 swollen joints and ≥ 6 tender joints (based on
66/68 joint count excluding distal interphalangeal joints) at screening and baseline
and at least 1 of the following at screening:

- erythrocyte sedimentation rate ≥ 28 mm/hr

- serum C-reactive protein > 1.0 mg/dL

- Subject has a positive rheumatoid factor or anti-cyclic citrullinated peptide at
screening.

- Subject has taken MTX for ≥ 12 consecutive weeks and is on a stable dose of oral or
subcutaneous MTX 7.5 to 25 mg/week for ≥ 8 weeks before receiving the investigational
product and is willing to remain on a stable dose throughout the study.

- For a subject on nonsteroidal anti-inflammatory drugs or low potency analgesics such
as tramadol, Soma Compounds, Fioricet, or Fiorinal, the dose should be stable for ≥ 2
weeks before screening.

- For a subject on oral corticosteroids (≤ 10 mg prednisone or equivalent), the dose
should be stable for ≥ 4 weeks before screening.

- Subject has no known history of active tuberculosis.

- Subject has a negative test for tuberculosis during screening defined as either:

- negative purified protein derivative (PPD) defined as < 5 mm of induration at 48
to 72 hours after test is placed

OR

- negative Quantiferon test

- Subject with a positive PPD and a history of Bacillus Calmette-Guérin vaccination
is allowed with a negative Quantiferon test.

- Subject with a positive PPD test (without a history of Bacillus Calmette-Guérin
vaccination) or a subject with a positive or indeterminate Quantiferon test is
allowed if they have all of the following:

- no symptoms of tuberculosis according to the worksheet provided by the sponsor, Amgen
Inc.

- documented history of adequate prophylaxis initiation before receiving investigational
product in accordance with local recommendations

- no known exposure to a case of active tuberculosis after most recent prophylaxis

Exclusion Criteria:

- Subject has a history of prosthetic or native joint infection.

- Subject has an active infection or history of infections as follows:

- any active infection for which systemic anti-infectives were used within 28 days
before first dose of investigational product

- a serious infection, defined as requiring hospitalization or intravenous (IV)
anti-infective(s) within 8 weeks before the first dose of investigational product

- recurrent or chronic infections or other active infection that, in the opinion of the
investigator, might cause this study to be detrimental to the subject

- Subject has a positive blood test for human immunodeficiency virus.

- Subject has a positive hepatitis B surface antigen, hepatitis B core antibody, or
hepatitis C virus antibody result at screening.

- Subject has uncontrolled, clinically significant systemic disease such as diabetes
mellitus, cardiovascular disease including moderate or severe heart failure (New York
Heart Association Class III/IV), renal disease, liver disease, or hypertension.

- Subject had a malignancy within 5 years EXCEPT for treated and considered cured
cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast
ductal carcinoma.

- Subject has a history of neurologic symptoms suggestive of central or peripheral
nervous system demyelinating disease.

- Subject has a major chronic inflammatory disease or connective tissue disease other
than RA, with the exception of secondary Sjögren's syndrome.

- Subject has a concurrent medical condition that, in the opinion of the investigator,
could cause this study to be detrimental to the subject.

- Subject has laboratory abnormalities at screening, including any of

the following:

- hemoglobin < 9 g/dL

- platelet count < 100 000/mm3

- white blood cell count < 3 000/mm3

- aspartate aminotransferase and/or alanine aminotransferase ≥ 2.0 x the upper limit of
normal

- creatinine clearance < 50 mL/min (Cockroft-Gault formula)

- any other laboratory abnormality, that, in the opinion of the investigator, will
prevent the subject from completing the study or will interfere with the
interpretation of the study results.

- Subject has used commercially available or investigational biologic therapies for
RA as follows:

- anakinra, etanercept within 1 month before the first dose of investigational product

- abatacept, tocilizumab, adalimumab, golimumab, certolizumab within 3 months before the
first dose of investigational product

- other experimental or commercially available biologic therapies for RA within 3 months
or 5 half-lives (whichever is longer) before the first dose of investigational product

- rituximab within 9 months before the investigational product along with evidence of
incomplete B cell recovery

- Subject has received live vaccines within 28 days before the first dose of
investigational product or plans to receive live vaccines during the course of
the study.

- Subject has previously received Remicade® (infliximab) or a biosimilar of
infliximab.

- Woman who is pregnant or breast feeding, or plans to become pregnant while
enrolled in the study and for 6 months after the last dose of investigational
product.

- Woman who is of childbearing potential (ie, neither surgically sterile nor
postmenopausal) and does not agree to use adequate contraception (eg, true
abstinence, sterilization, birth control pills, Depo-Provera®
[medroxyprogesterone] injections, or contraceptive implants) while on study and
for 6 months after the last dose of investigational product.